These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 33387296)

  • 41. Blinatumomab-induced T cell activation at single cell transcriptome resolution.
    Huo Y; Sheng Z; Lu DR; Ellwanger DC; Li CM; Homann O; Wang S; Yin H; Ren R
    BMC Genomics; 2021 Mar; 22(1):145. PubMed ID: 33648458
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A closer look at blinatumomab.
    Mattison RJ
    Clin Adv Hematol Oncol; 2018 Jun; 16(6):412-414. PubMed ID: 30067611
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Activity of blinatumomab in lymphoblastic leukemia with impaired T-cell immunity due to congenital immunodeficiency.
    Ramdeny S; Chaudhary A; Worth A; Ghorashian S; Slatter M; Lum SH; Vora A
    Blood Adv; 2021 Apr; 5(8):2153-2155. PubMed ID: 33881461
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cytofluorimetric assay to investigate variability in blinatumomab
    Braidotti S; Franca R; Granzotto M; Piscianz E; Tommasini A; Rabusin M; Stocco G; Decorti G
    Front Biosci (Landmark Ed); 2022 Jan; 27(2):39. PubMed ID: 35226982
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia.
    Rambaldi A; Ribera JM; Kantarjian HM; Dombret H; Ottmann OG; Stein AS; Tuglus CA; Zhao X; Kim C; Martinelli G
    Cancer; 2020 Jan; 126(2):304-310. PubMed ID: 31626339
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A novel method using blinatumomab for efficient, clinical-grade expansion of polyclonal T cells for adoptive immunotherapy.
    Golay J; D'Amico A; Borleri G; Bonzi M; Valgardsdottir R; Alzani R; Cribioli S; Albanese C; Pesenti E; Finazzi MC; Quaresmini G; Nagorsen D; Introna M; Rambaldi A
    J Immunol; 2014 Nov; 193(9):4739-47. PubMed ID: 25267972
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Blinatumomab activity in a patient with Down syndrome B-precursor acute lymphoblastic leukemia.
    Wadhwa A; Kutny MA; Xavier AC
    Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28921818
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Blinatumomab vs historic standard-of-care treatment for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukaemia.
    Gökbuget N; Dombret H; Giebel S; Brüggemann M; Doubek M; Foa R; Hoelzer D; Kim C; Martinelli G; Parovichnikova E; Maria Ribera J; Schoonen M; Tuglus C; Zugmaier G; Bassan R
    Eur J Haematol; 2020 Apr; 104(4):299-309. PubMed ID: 31876009
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study.
    Martinelli G; Boissel N; Chevallier P; Ottmann O; Gökbuget N; Topp MS; Fielding AK; Rambaldi A; Ritchie EK; Papayannidis C; Sterling LR; Benjamin J; Stein A
    J Clin Oncol; 2017 Jun; 35(16):1795-1802. PubMed ID: 28355115
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Imbalance of the CD226/TIGIT Immune Checkpoint Is Involved in the Pathogenesis of Primary Biliary Cholangitis.
    Deng C; Li W; Fei Y; Wang L; Chen Y; Zeng X; Zhang F; Li Y
    Front Immunol; 2020; 11():1619. PubMed ID: 32793241
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Potential clinical impact of T-cell lymphocyte kinetics monitoring in patients with B cell precursors acute lymphoblastic leukemia treated with blinatumomab: a single-center experience.
    Duminuco A; Markovic U; Parrinello NL; Lo Nigro L; Mauro E; Vetro C; Parisi M; Maugeri C; Fiumara PF; Milone G; Romano A; Di Raimondo F; Leotta S
    Front Immunol; 2023; 14():1195734. PubMed ID: 37809082
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia.
    Dombret H; Topp MS; Schuh AC; Wei AH; Durrant S; Bacon CL; Tran Q; Zimmerman Z; Kantarjian H
    Leuk Lymphoma; 2019 Sep; 60(9):2214-2222. PubMed ID: 30947585
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.
    Pillai V; Muralidharan K; Meng W; Bagashev A; Oldridge DA; Rosenthal J; Van Arnam J; Melenhorst JJ; Mohan D; DiNofia AM; Luo M; Cherian S; Fromm JR; Wertheim G; Thomas-Tikhonenko A; Paessler M; June CH; Luning Prak ET; Bhoj VG; Grupp SA; Maude SL; Rheingold SR
    Blood Adv; 2019 Nov; 3(22):3539-3549. PubMed ID: 31738832
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Blinatumomab as a bridge to further therapy in cases of overwhelming toxicity in pediatric B-cell precursor acute lymphoblastic leukemia: Report from the Israeli Study Group of Childhood Leukemia.
    Elitzur S; Arad-Cohen N; Barzilai-Birenboim S; Ben-Harush M; Bielorai B; Elhasid R; Feuerstein T; Gilad G; Gural A; Kharit M; Litichever N; Nirel R; Weinreb S; Wolach O; Toren A; Izraeli S; Jacoby E
    Pediatr Blood Cancer; 2019 Oct; 66(10):e27898. PubMed ID: 31264788
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia.
    Gökbuget N; Zugmaier G; Dombret H; Stein A; Bonifacio M; Graux C; Faul C; Brüggemann M; Taylor K; Mergen N; Reichle A; Horst HA; Havelange V; Topp MS; Bargou RC
    Leuk Lymphoma; 2020 Nov; 61(11):2665-2673. PubMed ID: 32619115
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase 1b/2 study of blinatumomab in Japanese adults with relapsed/refractory acute lymphoblastic leukemia.
    Kiyoi H; Morris JD; Oh I; Maeda Y; Minami H; Miyamoto T; Sakura T; Iida H; Tuglus CA; Chen Y; Dos Santos C; Kalabus J; Anderson A; Hata T; Nakashima Y; Kobayashi Y
    Cancer Sci; 2020 Apr; 111(4):1314-1323. PubMed ID: 31971321
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A review of blinatumomab, a novel immunotherapy.
    Newman MJ; Benani DJ
    J Oncol Pharm Pract; 2016 Aug; 22(4):639-45. PubMed ID: 26607163
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Day 15 bone marrow minimal residual disease predicts response to blinatumomab in relapsed/refractory paediatric B-ALL.
    Brown P; Zugmaier G; Gore L; Tuglus CA; von Stackelberg A
    Br J Haematol; 2020 Feb; 188(4):e36-e39. PubMed ID: 31797346
    [No Abstract]   [Full Text] [Related]  

  • 59. Blinatumomab for the treatment of adult acute lymphoblastic leukemia.
    Dahl J; Mace M; Kantarjian H; Jabbour E
    Drugs Today (Barc); 2015 Apr; 51(4):231-41. PubMed ID: 26020065
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.
    Gökbuget N; Dombret H; Bonifacio M; Reichle A; Graux C; Faul C; Diedrich H; Topp MS; Brüggemann M; Horst HA; Havelange V; Stieglmaier J; Wessels H; Haddad V; Benjamin JE; Zugmaier G; Nagorsen D; Bargou RC
    Blood; 2018 Apr; 131(14):1522-1531. PubMed ID: 29358182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.